Phase 1 Dexlansoprazole Delayed-Release Capsules for Acid-Related Disorders in Infants Aged 1 to 11 Months
Status:
Withdrawn
Trial end date:
2025-12-23
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the pharmacokinetics (PK) and pharmacodynamics (PD)
[after daily administration for 7 days] and safety [after daily administration for 8 weeks]
of dexlansoprazole in pediatric participants aged 1 to 11 months, inclusive, with
acid-related diseases.